title: Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer?
authors.forename: F
authors.initials: F
authors.lastname: Boccardo
authors.forename: L
authors.initials: L
authors.lastname: Miglietta
authors.forename: M
authors.initials: M
authors.lastname: Bruzzone
authors.forename: A
authors.initials: A
authors.lastname: Rubagotti
authors.forename: M C
authors.initials: MC
authors.lastname: Locatelli
authors.forename: N
authors.initials: N
authors.lastname: Ragni
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D017410:Practice Guidelines as Topic
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D017239:Paclitaxel; D002945:Cisplatin